Association of Increased Treg Cell Levels With Elevated Indoleamine 2,3-Dioxygenase Activity and an Imbalanced Kynurenine Pathway in Interferon-Positive Primary Sjögren's Syndrome

Arthritis and Rheumatology

Volumn 68, Issue 7, 2016, Pages 1688-1699

  Maria, Naomi I ^a   van Helden Meeuwsen, Cornelia G ^a   Brkic, Zana ^a   Paulissen, Sandra M J ^a   Steenwijk, Eline C ^a   Dalm, Virgil A ^a   van Daele, Paul L ^a   Martin van Hagen, P ^a   Kroese, Frans G M ^b   van Roon, Joel A G ^c   Harkin, Andrew ^d   Dik, Willem A ^a   Drexhage, Hemmo A ^a   Lubberts, Erik ^a   Versnel, Marjan A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD45RO ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INTERFERON; KYNURENINE; KYNURENINE 3 MONOOXYGENASE; KYNURENINE AMINOTRANSFERASE; KYNURENINE AMINOTRANSFERASE I; KYNURENINE AMINOTRANSFERASE III; KYNURENINE AMINOTRANSFERASE IV; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3; TRYPTOPHAN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL SELECTION; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INDUCTION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOPATHOGENESIS; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; MONOCYTE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; SJOEGREN SYNDROME;

EID: 84976582003     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39629     Document Type: Article

References (50)

1. Fox RI, Howell FV, Bone RC, Michelson P. Primary Sjögren syndrome: clinical and immunopathologic features. Semin Arthritis Rheum 1984;14:77–105.
2. Fox RI, Kang HI. Pathogenesis of Sjögren's syndrome. Rheum Dis Clin North Am 1992;18:517–38.
3. Nguyen CQ, Peck AB. Unraveling the pathophysiology of Sjögren syndrome-associated dry eye disease. Ocul Surf 2009;7:11–27.
4. Brkic Z, Maria NI, van Helden-Meeuwsen CG, van de Merwe JP, van Daele PL, Dalm VA, et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjögren's syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis 2013;72:728–35.
5. Maria NI, Brkic Z, Waris M, van Helden-Meeuwsen CG, Heezen K, van de Merwe JP, et al. MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjögren's syndrome. Ann Rheum Dis 2014;73:1052–9.
6. Emamian ES, Leon JM, Lessard CJ, Grandits M, Baechler EC, Gaffney PM, et al. Peripheral blood gene expression profiling in Sjögren's syndrome. Genes Immun 2009;10:285–96.
7. Mackay F, Groom JR, Tangye SG. An important role for B-cell activation factor and B cells in the pathogenesis of Sjögren's syndrome. Curr Opin Rheumatol 2007;19:406–13.
8. Mariette X, Seror R, Quartuccio L, Baron G, Salvin S, Fabris M, et al. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis 2015;74:526–31.
9. Hall JC, Casciola-Rosen L, Berger AE, Kapsogeorgou EK, Cheadle C, Tzioufas AG, et al. Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proc Natl Acad Sci U S A 2012;109:17609–14.
10. Hall JC, Baer AN, Shah AA, Criswell LA, Shiboski CH, Rosen A, et al. Molecular subsetting of interferon pathways in Sjögren's syndrome. Arthritis Rheumatol 2015;67:2437–46.
11. Nezos A, Gravani F, Tassidou A, Kapsogeorgou EK, Voulgarelis M, Koutsilieris M, et al. Type I and II interferon signatures in Sjögren's syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjögren's related lymphomagenesis. J Autoimmun 2015;63:47–58.
12. Puccetti P. On watching the watchers: IDO and type I/II IFN. Eur J Immunol 2007;37:876–9.
13. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 2012;13:465–77.
14. Nemeth H, Toldi J, Vecsei L. Role of kynurenines in the central and peripheral nervous systems. Curr Neurovasc Res 2005;2:249–60.
15. Mandi Y, Vecsei L. The kynurenine system and immunoregulation. J Neural Transm (Vienna) 2012;119:197–209.
16. Campbell BM, Charych E, Lee AW, Moller T. Kynurenines in CNS disease: regulation by inflammatory cytokines. Front Neurosci 2014;8:12.
17. Chen W. IDO: more than an enzyme. Nat Immunol 2011;12:809–11.
18. Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003;4:1206–12.
19. Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol 2011;12:870–8.
20. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor ζ-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006;176:6752–61.
21. high regulatory T cells by promoting maturation of LPS-treated dendritic cells. Eur J Immunol 2007;37:3054–62.
22. Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 2003;24:242–8.
23. Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010;11:7–13.
24. Campbell DJ, Koch MA. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol 2011;11:119–30.
25. Bacher N, Raker V, Hofmann C, Graulich E, Schwenk M, Baumgrass R, et al. Interferon-α suppresses cAMP to disarm human regulatory T cells. Cancer Res 2013;73:5647–56.
26. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al, and the European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554–8.
27. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al, on behalf of the EULAR Sjögren's Task Force. EULAR Sjögren's Syndrome Disease Activity Index: development of a consensus systemic disease activity index for primary Sjögren's syndrome. Ann Rheum Dis 2010;69:1103–9.
28. Gibney SM, Fagan EM, Waldron AM, O'Byrne J, Connor TJ, Harkin A. Inhibition of stress-induced hepatic tryptophan 2,3-dioxygenase exhibits antidepressant activity in an animal model of depressive behaviour. Int J Neuropsychopharmacol 2014;17:917–28.
29. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)—a Europe Against Cancer program. Leukemia 2003;17:2474–86.
30. CT method. Methods 2001;25:402–8.
31. Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG, et al. Coordinate overexpression of interferon-α–induced genes in systemic lupus erythematosus. Arthritis Rheum 2004;50:3958–67.
32. Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:2951–62.
33. Van Hamburg JP, Mus AM, de Bruijn MJ, de Vogel L, Boon L, Cornelissen F, et al. GATA-3 protects against severe joint inflammation and bone erosion and reduces differentiation of Th17 cells during experimental arthritis. Arthritis Rheum 2009;60:750–9.
34. Laich A, Neurauter G, Widner B, Fuchs D. More rapid method for simultaneous measurement of tryptophan and kynurenine by HPLC. Clin Chem 2002;48:579–81.
35. Pertovaara M, Raitala A, Uusitalo H, Pukander J, Helin H, Oja SS, et al. Mechanisms dependent on tryptophan catabolism regulate immune responses in primary Sjögren's syndrome. Clin Exp Immunol 2005;142:155–61.
36. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, Maes M. IDO and interferon-α-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005;10:538–44.
37. Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol 2013;34:137–43.
38. Fallarino F, Grohmann U, Puccetti P. Indoleamine 2,3-dioxygenase: from catalyst to signaling function. Eur J Immunol 2012;42:1932–7.
39. Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein HG, Sarnyai Z, et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? [published erratum appears in J Neuroinflammation 2013;10:34]. J Neuroinflammation 2011;8:94.
40. Agudelo LZ, Femenia T, Orhan F, Porsmyr-Palmertz M, Goiny M, Martinez-Redondo V, et al. Skeletal muscle PGC-1α1 modulates kynurenine metabolism and mediates resilience to stress-induced depression. Cell 2014;159:33–45.
41. Van Hamburg JP, Corneth OB, Paulissen SM, Davelaar N, Asmawidjaja PS, Mus AM, et al. IL-17/Th17 mediated synovial inflammation is IL-22 independent. Ann Rheum Dis 2013;72:1700–7.
42. Vitali C, Prafioriti A, Sambataro D, Di Bernardo A, Admiraglio E, Nayar S, et al. Expression of indoleamine 2,3 dioxygenase-1 and -2 in focal sialoadenitis of patients with Sjögren's syndrome [abstract]. Arthritis Rheum 2014;66 Suppl:S230–1.
43. Alunno A, Carubbi F, Bistoni O, Caterbi S, Bartoloni E, Mirabelli G, et al. T regulatory and T helper 17 cells in primary Sjögren's syndrome: facts and perspectives. Mediators Inflamm 2015;2015:243723.
44. high regulatory T cells are not impaired in patients with primary Sjögren's syndrome. J Autoimmun 2005;24:235–42.
45. + regulatory T cells and allows expansion of alloreactive and autoreactive T cells. J Immunol 2012;189:5649–58.
46. Bikker A, van Woerkom JM, Kruize AA, Wenting-van Wijk M, de Jager W, Bijlsma JW, et al. Increased expression of interleukin-7 in labial salivary glands of patients with primary Sjögren's syndrome correlates with increased inflammation. Arthritis Rheum 2010;62:969–77.
47. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 1991;56:2007–17.
48. Vecsei L, Szalardy L, Fulop F, Toldi J. Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov 2013;12:64–82.
49. Saito K, Crowley JS, Markey SP, Heyes MP. A mechanism for increased quinolinic acid formation following acute systemic immune stimulation. J Biol Chem 1993;268:15496–503.
50. Heyes MP, Saito K, Major EO, Milstien S, Markey SP, Vickers JH. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease: attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate. Brain 1993;116:1425–50.